Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 289

The DOI matches its Crossref record; 525 of the 525 references it cites were found in a registry or an index.

Monoaminergic neuropathology in Alzheimer’s disease

Open access
Šimić, Goran, Babić Leko, Mirjana, Wray, Selina, Harrington, Charles R., Delalle, Ivana, Jovanov-Milošević, Nataša, Bažadona, Danira, Buée, Luc, de Silva, Rohan, Di Giovanni, Giuseppe, Wischik, Claude M., Hof, Patrick R.·2017·Progress in Neurobiology

Abstract

HighlightsMonoaminergic systems are altered in Alzheimer's disease.Noradrenergic LC and serotonergic DRN are among the first affected by tau pathology.Changes in DRN and LC lead to the deterioration of the sleep‐wake cycle in AD.Depression in preclinical AD further indicates monoaminergic alteration in AD.In view of its early involvement in AD, the serotonergic system could serve as a therapeutic target. ABSTRACT None of the proposed mechanisms of Alzheimer's disease (AD) fully explains the distribution patterns of the neuropathological changes at the cellular and regional levels, and their clinical correlates. One aspect of this problem lies in the complex genetic, epigenetic, and environmental landscape of AD: early‐onset AD is often familial with autosomal dominant inheritance, while the vast majority of AD cases are late‐onset, with the &egr;4 variant of the gene encoding apolipoprotein E (APOE) known to confer a 5–20 fold increased risk with partial penetrance. Mechanisms by which genetic variants and environmental factors influence the development of AD pathological changes, especially neurofibrillary degeneration, are not yet known. Here we review current knowledge of the involvement of the monoaminergic systems in AD. The changes in the serotonergic, noradrenergic, dopaminergic, histaminergic, and melatonergic systems in AD are briefly described. We also summarize the possibilities for monoamine‐based treatment in AD. Besides neuropathologic AD criteria that include the noradrenergic locus coeruleus (LC), special emphasis is given to the serotonergic dorsal raphe nucleus (DRN). Both of these brainstem nuclei are among the first to be affected by tau protein abnormalities in the course of sporadic AD, causing behavioral and cognitive symptoms of variable severity. The possibility that most of the tangle‐bearing neurons of the LC and DRN may release amyloid &bgr; as well as soluble monomeric or oligomeric tau protein trans‐synaptically by their diffuse projections to the cerebral cortex emphasizes their selective vulnerability and warrants further investigations of the monoaminergic systems in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pneurobio.2016.04.001

Cites

525 of 525 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 525 references

Cited by

See all 289

Metadata

Authors
Šimić, G., Babić Leko, M., Wray, S., Harrington, C. R., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Di Giovanni, G., Wischik, C. M., & Hof, P. R.
Venue
Progress in Neurobiology
Publisher
Elsevier BV
Published
2017-04
Volume
151
Pages
101-138
ISSN
0301-0082 (ISSN-L)
OpenAlex
W2336131134
Cited by
289
References
525
FWCI
16.88
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monoaminergic neuropathology in Alzheimer’s disease. https://app.cochat.ai/papers/10.1016/j.pneurobio.2016.04.001
The paper
Šimić, G., Babić Leko, M., Wray, S., Harrington, C. R., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Di Giovanni, G., Wischik, C. M., & Hof, P. R. (2017). Monoaminergic neuropathology in Alzheimer’s disease. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2016.04.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.